Sarepta Therapeutics Inc SRPT reported fourth-quarter results Wednesday alongside positive results for its muscular dystrophy gene therapy candidate.
Janney analyst Yun Zhong reiterated a Buy rating on Sarepta with a $200 fair value estimate.
Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating and increased the price target from $217 to $231.
Janney: Strong Balance Sheet Needed For Active Clinical Program
Sarepta continues to move ahead with its gene therapy and exon-skipping pipelines, Zhong said in a Thursday note.
The company will initiate a multicenter registrational study of microdystrophin gene therapy using commercial-scale material by the end of 2019, the analyst said.
Sarepta is seeking to discuss a regulatory pathway for all five limb-girdle muscular dystrophy, or LGMD, gene therapy programs with the FDA, Zhong said.
Janney projects that Sarepta will more than double the exon-skipping market in 2020, given the scheduling of the golodirsen PDUFA date for August and the potential for a midyear NDA submission for casimersen.
Reviewing the results, Janney attributed Sarepta's fourth-quarter loss to upfront and milestone payments due to gene therapy partners Lysogene and Myonexus.
Even as the company forecast an increase in operating expenses due to gene therapy manufacturing, Zhong said a strengthened balance sheet should support its "increasingly active" clinical development.
Cantor Sees Compelling LGMD Opportunity
The limb girdle data released Wednesday exceeded expectations, Young said in a Thursday note. The analyst views the collective LGMD opportunity as a compelling one, with a target population similar to DMD, with over 10,000 patients in the U.S.
The analyst said she hopes to get further updates on LGMD development strategy later this year following regulatory interactions. The Paragon commercial manufacturing facility is expected to be ready by the first quarter of 2020, Young said.
"We have raised our probability of success for MYO-101, '103 and '201 to 50 percent from 25 percent and left MYO-102 and '301 programs unchanged."
Cantor sees meaningful read-through across these programs because they use a similar approach.
The Price Action
After advancing 8.3 percent Wednesday, Sarepta shares were slipping 4.27 percent to $145.21 at the time of publication Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.